Current Practices, Perceived Barriers, and Promising Implementation Strategies for Improving Quality of Smoking Cessation Support in Accredited Cancer Programs of the American College of Surgeons This ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...

Molecular and genetic testing has become a game-changer in brain tumor care - shaping diagnosis, guiding treatments and opening doors to new therapies. Once available to a handful of patients, these ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...

The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, driven by expanding precision medicine adoption and advanced genetic testing. North America leads the market, ...

As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.